Literature DB >> 4881983

The LSD syndrome. A review.

H H Eveloff.   

Abstract

lsd (lysergic acid diethylamide) is a powerful bio-active substance related to serotonin in structure. Its actions generally affect autonomic, sensory and psychological functions. Autonomic stimulation is varied. Sensory responses are usually visual, involving heightened and distorted color perception and fusion of sensory impressions. Psychological responses include a feeling that a unique experience is occurring; feelings of depersonalization; pronounced fluctuation of mood; time and space distortions; autistic phenomena; fluctuation of aggressive drives (usually reduction); and spontaneous reoccurrence of the lsd experience. THE SUBJECTIVE RESPONSES CAN BE RELATED TO THREE BASIC PHENOMENA: (1) expectation; (2) loss of characteristic modes of perceptual and cognitive patterning; and (3) hypersuggestibility. THE MAJOR ADVERSE REACTIONS ARE: (1) chronic drug dependence including subsequent personality changes and depressive reactions; and (2) acute ego dissolution. These reactions usually occur in already emotionally ill people. Most of these users fall into two groups, those with unresolved identity problems and those with severe ego abnormality. The majority of adverse reactions are of the chronic drug dependence type and are usually seen in adolescents and young adults who have not negotiated the age-appropriate tasks of forming and integrating the various identities that are the composite of their life experiences.lsd helps alleviate these stresses via some of its psychological properties as discussed. It also provides a nidus for the formation of a subculture where goals for social, sexual and vocational achievement are lower and idiosyncratic modes of adaptation are better tolerated. A smaller group of users who have serious reactions such as psychosis, rage reactions, homicidal and suicidal ideation are usually found to have preexisting ego abnormality such as ambulatory schizophrenia, chronic impulse disorders and borderline states. Although adverse reactions most often appear to be related to pre-morbid psychopathology, this is not invariably so. Further, there is as yet no reliable method to determine who will have an adverse reaction and what the nature of that reaction will be.

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 4881983      PMCID: PMC1503329     

Source DB:  PubMed          Journal:  Calif Med        ISSN: 0008-1264


  8 in total

1.  Prolonged adverse reactions to lysergic acid diethylamide.

Authors:  S COHEN; K S DITMAN
Journal:  Arch Gen Psychiatry       Date:  1963-05

2.  Effects of LSD-25 on brain serotonin.

Authors:  D X FREEDMAN
Journal:  J Pharmacol Exp Ther       Date:  1961-11       Impact factor: 4.030

3.  Patterns of tolerance to lysergic acid diethylamide and mescaline in rats.

Authors:  D X FREEDMAN; G K AGHAJANIAN; E M ORNITZ
Journal:  Science       Date:  1958-05-16       Impact factor: 47.728

4.  Untoward reactions to lysergic acid diethylamide (LSD) resulting in hospitalization.

Authors:  W A Frosch; E S Robbins; M Stern
Journal:  N Engl J Med       Date:  1965-12-02       Impact factor: 91.245

5.  The dangers of LSD. Analysis of seven months' experience in a university hospital's psychiatric service.

Authors:  J T Ungerleider; D D Fisher; M Fuller
Journal:  JAMA       Date:  1966-08-08       Impact factor: 56.272

6.  "Psychedelic" experiences in acute psychoses.

Authors:  M B Bowers; D X Freedman
Journal:  Arch Gen Psychiatry       Date:  1966-09

7.  Prolonged adverse reactions to LSD in psychotic subjects.

Authors:  M Fink; J Simeon; W Haque; T Itil
Journal:  Arch Gen Psychiatry       Date:  1966-11

8.  Studies on lysergic acid diethylamide (LSD-25). I. Effects in former morphine addicts and development of tolerance during chronic intoxication.

Authors:  R E BELLEVILLE; H F FRASER; H ISBELL; C R LOGAN; A WIKLER
Journal:  AMA Arch Neurol Psychiatry       Date:  1956-11
  8 in total
  3 in total

Review 1.  Lysergic acid diethylamide: a drug of 'use'?

Authors:  Saibal Das; Preeti Barnwal; Anand Ramasamy; Sumalya Sen; Somnath Mondal
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-23

Review 2.  Perspectives on zebrafish models of hallucinogenic drugs and related psychotropic compounds.

Authors:  Nikhil Neelkantan; Alina Mikhaylova; Adam Michael Stewart; Raymond Arnold; Visar Gjeloshi; Divya Kondaveeti; Manoj K Poudel; Allan V Kalueff
Journal:  ACS Chem Neurosci       Date:  2013-08-06       Impact factor: 4.418

3.  Ego-Dissolution and Psychedelics: Validation of the Ego-Dissolution Inventory (EDI).

Authors:  Matthew M Nour; Lisa Evans; David Nutt; Robin L Carhart-Harris
Journal:  Front Hum Neurosci       Date:  2016-06-14       Impact factor: 3.169

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.